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OBJECTIVES: Economic evaluations in oncology require estimating survival bene-
fits which is used to obtain quality adjusted life years (QALYs) and incremental
cost-effectiveness ratios (ICERs). However, few guidelines exist on how survival
data should be analyzed and extrapolated to obtain full survival benefit for eco-
nomic evaluation. A recent NICE Decision Support Unit document details an algo-
rithm for selecting survival models for economic evaluations alongside clinical
trials. We use this algorithm and other published literature to demonstrate how
different models lead to varying survival estimates and how survival data can be
systematically assessed in a patient registry using patient-level data. METHODS:
Data from the National Cancer Institute’s Surveillance Epidemiology and End Re-
sults (SEER) were used. Surgical treatment for prostate cancer was used to illustrate
the methods, but the approach is transferrable to other cancers and treatment
strategies. Patients diagnosed with prostate cancer (PC) between 1991 and 2001
were included, the sample was limited to stage IV PC patients. Survival between
surgery and non-surgery group was estimated via Kaplan Meier, parametric and
semi-parametric methods. Several model fit criteria’s such as visual inspection,
log-cumulative hazard plots, Cox-Snell residuals, Akaike Information Criterion
(AIC), Bayesian Information Criterion (BIC) along with proportionality assumption
tests were used to select appropriate method and distribution. Observed and ex-
trapolated mean estimates were calculated and compared. RESULTS: Analysis in-
dicated that survival time and benefit differed based on the model selected. Our
case example demonstrated the best fit was with Weibull and exponential distri-
butions – however, consideration must also be given to the tail in any extrapolation
of the parametric distributions selected. CONCLUSIONS: Systematic analysis of
survival data is an important evaluation criterion by health technology assess-
ments. Selection of survival models must be justified using appropriate steps as
different models can yield varying estimates, and improper selection can translate
to incorrect estimation of QALYs and the resulting ICERs.
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OBJECTIVES: To investigate the merits and challenges with calibrating Bayesian
multiple treatment comparison meta-analysis (MTC) with cost-effectiveness (CE)
analysis, in particular, construction of multiple cost-effectiveness acceptability
curves and cost-effectiveness frontiers. METHODS: We calibrated a Bayesian MTC
of pharmacotherapies for chronic obstructive pulmonary disease with a Bayesian
CE markov model. We simulated 10000 observations and derived multiple cost-
effectiveness acceptability curves for each of the treatments as well as the cost-
effectiveness frontier. We separately repeated the analyses based on pair-wise
meta-analysis estimates of treatment effectiveness. We compared the two ap-
proaches with respect to precision and inferred reasonable CE thresholds.
RESULTS: The MTC approach generally yielded higher precision, and thus, had
higher certainty surrounding the inferred CE thresholds. This was especially the
case for comparisons with treatments in the extended dominance region, but close
to the cost-effective treatments. CONCLUSIONS: Calibration of Bayesian multiple
treatment comparison meta-analysis and Bayesian multiple cost-effectiveness ac-
ceptability curves appears to improve precision compared with the conventional
approach.
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OBJECTIVES: Cost-effectiveness assessment using real-life data is important to
improve health care management. We applied marginal structural models (MSMs)
to evaluate cost-effectiveness of statin therapy and medication adherence in the
secondary prevention of acute myocardial infarction (AMI), using health care ad-
ministrative databases (HADs). METHODS: This is an observational longitudinal
study based on HADs of the national health care system in Lombardy, a region in
Northern Italy with about 9 millions of inhabitants. Patients hospitalized in 2003 for
their first episode of AMI were followed until December 31, 2008, collecting data on
health care services and vital status. Persistence and adherence to statin were
measured as time-dependent variables. We adopted a net-benefit regression ap-
proach with related acceptability curves, using direct medical costs and gained
life-years as outcomes. MSMs accounted for the dynamic interactive effects be-
tween treatment and the time-varying confounders, i.e. non-fatal cardiovascular
(CV) events and others CV therapies. RESULTS: A total of 11,706 individuals (65%
men) with a mean age of 70 years, were hospitalized for their first AMI during 2003.
26% of patients died during a median follow-up time of 5 years. The mean annul
total cost per patient was €4,348 (95%CI: 4,264-4,408), 59% of which was attributable
to CV diagnosis. Statin reduced the risk of death and medication adherence af-
fected risk reduction. The incremental net-benefit of statin therapy was positive
for values of willingness to pay (WTP) equal or greater than €0. The probability
that statin therapy was cost-effective was 50% for WTP equal to €0 and about
75% for values equal or greater than €250. Medication adherence influenced
cost-effectiveness. CONCLUSIONS: MSMs can be used in economic health care
evaluations to account for time-varying confounding, trying to minimize the po-
tential biases of longitudinal observational studies. This study confirms cost-effec-
tiveness of statin therapy for secondary prevention in real-life settings and sug-
gests further investigations on adherence effects.
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OBJECTIVES: Since 2001 in Italy several regions have introduced a fixed co-pay-
ment with some differences in the amount and exemptions. The aim of the study
was to assess, through a time-series analysis, the effect of the introduction of the
co-payment on pharmaceutical consumption, using, as case study, two Italian
regions: Piemonte and Puglia. METHODS: Monthly data between January 2000 and
December 2010 related to both public and private outpatient consumption were
used in the analysis. Public consumption data were obtained from AIFA’s Medi-
cines Utilisation Monitoring Centre (OsMeD); conversely, data on private consump-
tion were obtained as difference between the total consumption (private and pub-
lic) provided by IMS Health and public consumption. The data were expressed in
Defined Daily Doses (DDD) per 1000 inhabitants. A segmented regression analysis
was performed, controlling for the autocorrelation. RESULTS: In Piemonte Region
the introduction of co-payment had an immediate significant effect on public con-
sumption with a reduction of 74 DDD per 1000 inhabitants (p-value 0.007). The
private consumption showed a significant increase of 119 DDD per 1000 inhabit-
ants (p-value 0.03) after the introduction of the co-payment. In Puglia Region the
co-payment didn’t have the expected outcome; in fact both public and private
consumption increased after the intervention. In the long term the public con-
sumption steadily grew and there was a significant reduction in private
consumption. CONCLUSIONS: The introduction of co-payment didn’t have the
expected effect in reducing the over consumption. In Piemonte Region the reduc-
tion of public consumption was balanced by the increase in private consumption
(substitution effect). In Puglia Region the co-payment resulted in a lowering of private
consumption, probably due to fewer available economic resources (income effect),
and didn’t have any effect on public consumption.
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OBJECTIVES: Insomnia is mostly treated by benzodiazepine (BZD) or Z-drugs that
are efficacious but are also associated with safety issues like dependence and re-
bound insomnia. These safety concerns may present a major public health issue,
particularly for the elderly. Prolonged-release (PR) melatonin is a non-sedative
hypnotic that has demonstrated clinically relevant efficacy on quality of sleep and
morning alertness, with a good safety profile. Several clinical trials demonstrated
that the PR-melatonin could help reduce BZD/Z-drugs consumption. The objective
is to analyze the impact of anti-BZD/Z-drug campaigns and the availability of PR-
melatonin on the consumption of BZD/Z-drugs. METHODS: Nine European coun-
tries were studied. For each one, we studied the evolution of BZD/Z-drug sales
volumes related to: the launch strategy of PR-melatonin, anti-BZD/Z drug cam-
paigns, the market uptake of PR-melatonin and its reimbursement status. The
sales differences from 2005 were interpreted graphically for BZD, Z-drugs and
PR-melatonin. RESULTS: Three types of countries were identified: -Countries
where the sales of BZD/Z-drugs decreased since 2007: Greece, Finland and Den-
mark. - Countries where the sales of BZD decreased while Z-drugs increased: Nor-
way, the Netherlands and the UK. The anti-BZD campaigns seem effective for
BZDs, but essentially resulted in the shift in prescription patterns towards Z-drugs.
- Countries where the sales of BZD were stable and Z-drugs increased resulting in
an overall increase in BZD/Z-drug sales despite anti-BZD/Z campaigns: France,
Sweden and Spain. Campaigns aiming to reduce the use of BZD/Z-drugs failed
when they were not associated with the availability and market uptake of PR-
melatonin. The reimbursement of PR-melatonin supports better penetration rates
and a higher reduction in sales for BZD/Z-drugs. The disreimbursement of BZD/Z-
drugs did not have any effect on Z-drug prescriptions, with an increase noted
during 2011. CONCLUSIONS: Policy makers wishing to change drug utilization pat-
terns should consider the availability of pharmacological alternatives.
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OBJECTIVES: A recent study[1] by the Tufts Center for the Study of Drug Develop-
ment indicated that Central Nervous System (CNS) drugs take 35% longer to de-
velop and are less likely to gain approval compared to other new prescription
medicines. Once approved in Europe, Transparency Directive 89/105/EEC requires
countries to determine pricing and reimbursement (P&R) within 180 days but this
target is not always met. This study evaluated the time required to achieve P&R and
to launch CNS products in Europe to quantify how such delays impact patients and
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